24/7 Market News Snapshot 09 June, 2025 – Citius Oncology, Inc. Common Stock (NASDAQ:CTOR)

June 9, 2025

DENVER, Colo., 09 June, 2025 (www.247marketnews.com) – (NASDAQ:CTOR) are discussed in this article.
Citius Oncology, Inc. is currently witnessing an impressive surge in its stock price, reflecting heightened investor interest and optimism in the company’s prospects. As of the latest pre-market trading, shares have risen by 34.27% to $1.410, moving significantly from the previous close of $1.050. The trading volume, with 4.90 million shares exchanged, signifies strong momentum that investors are urged to closely observe, as it may herald positive developments for the biotech firm.

In addition to the stock performance, Citius Oncology has made a strategic advancement by securing a distribution agreement with Cardinal Health. This pivotal collaboration aims to enhance accessibility to its innovative immunotherapy, LYMPHIR™ (denileukin diftitox-cxdl), ahead of its anticipated U.S. market launch. Already approved by the FDA for treating adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), LYMPHIR represents a critical therapeutic option for patients facing this challenging condition.

Leonard Mazur, Citius Oncology’s Chairman and CEO, emphasized the importance of this agreement for their launch readiness. He noted that Cardinal Health’s established distribution capabilities would be instrumental in ensuring that LYMPHIR reaches healthcare providers and patients in a timely and efficient manner, thereby reinforcing their commercial distribution network.

LYMPHIR specifically targets IL-2 receptors found on cancerous cells, leveraging a diphtheria toxin to disrupt protein synthesis and induce cell death. This innovative treatment is positioned to address a market exceeding $400 million, which remains underserved by existing therapies. As Citius Oncology advances its initiatives, it seeks not only to improve patient outcomes but also to solidify its standing within the oncology sector, paving the way for future innovations in cancer treatment.

Related news for (CTOR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.